149 related articles for article (PubMed ID: 24596357)
1. Pemetrexed-induced radiation recall dermatitis of the breast.
Boesmans S; Decoster L; Schallier D
Anticancer Res; 2014 Mar; 34(3):1179-82. PubMed ID: 24596357
[TBL] [Abstract][Full Text] [Related]
2. Radiation recall dermatitis with pemetrexed.
Hureaux J; Le Guen Y; Tuchais C; Savary L; Urban T
Lung Cancer; 2005 Nov; 50(2):255-8. PubMed ID: 16111784
[TBL] [Abstract][Full Text] [Related]
3. Unsuccessful rechallenge with pemetrexed after a previous radiation recall dermatitis.
Barlési F; Tummino C; Tasei AM; Astoul P
Lung Cancer; 2006 Dec; 54(3):423-5. PubMed ID: 17049669
[TBL] [Abstract][Full Text] [Related]
4. Pemetrexed: a multitargeted antifolate.
Rollins KD; Lindley C
Clin Ther; 2005 Sep; 27(9):1343-82. PubMed ID: 16291410
[TBL] [Abstract][Full Text] [Related]
5. Pemetrexed: new drug. Pleural mesothelioma: a first encouraging trial.
Prescrire Int; 2005 Dec; 14(80):212-4. PubMed ID: 16400741
[TBL] [Abstract][Full Text] [Related]
6. Pemetrexed-induced hyperpigmentation of the skin.
Schallier D; Decoster L; de Greve J
Anticancer Res; 2011 May; 31(5):1753-5. PubMed ID: 21617235
[TBL] [Abstract][Full Text] [Related]
7. Interstitial pneumonitis after treatment with pemetrexed: a rare event?
Hochstrasser A; Benz G; Joerger M; Templeton A; Brutsche M; Früh M
Chemotherapy; 2012; 58(1):84-8. PubMed ID: 22377772
[TBL] [Abstract][Full Text] [Related]
8. Pemetrexed-associated urticarial vasculitis.
Lopes G; Vincek V; Raez LE
Lung Cancer; 2006 Feb; 51(2):247-9. PubMed ID: 16360237
[TBL] [Abstract][Full Text] [Related]
9. [Pemetrexed nephrotoxicity].
Izzedine H
Bull Cancer; 2015 Feb; 102(2):190-7. PubMed ID: 25641712
[TBL] [Abstract][Full Text] [Related]
10. Maintenance therapy with pemetrexed versus docetaxel after induction therapy with carboplatin and pemetrexed in chemotherapy-naïve patients with advanced non-squamous non-small-cell lung cancer: a randomized, phase II study.
Karayama M; Inui N; Kuroishi S; Yokomura K; Toyoshima M; Shirai T; Masuda M; Yamada T; Yasuda K; Suda T; Chida K
Cancer Chemother Pharmacol; 2013 Aug; 72(2):445-52. PubMed ID: 23807323
[TBL] [Abstract][Full Text] [Related]
11. Acute generalized exanthematous pustulosis after pemetrexed, and recurrence after re-introduction.
Bracke A; Van Marck E; Lambert J
Clin Exp Dermatol; 2009 Apr; 34(3):337-9. PubMed ID: 18699838
[TBL] [Abstract][Full Text] [Related]
12. Toxic epidermal necrolysis after pemetrexed and cisplatin for non-small cell lung cancer in a patient with sharp syndrome.
Then C; von Einem JC; Müller D; Flaig MJ; Huber RM; Reincke M
Onkologie; 2012; 35(12):783-6. PubMed ID: 23207626
[TBL] [Abstract][Full Text] [Related]
13. [Adverse events during pemetrexed administration caused by concomitant nonsteroid anti-inflammatory therapy].
Sakata Y; Iwamoto Y; Inata J; Matsumoto S; Miyamori S; Nakashima K; Sakamoto S; Kanehara M; Kitaguchi S; Hiraki K
Gan To Kagaku Ryoho; 2012 Jun; 39(6):927-32. PubMed ID: 22705687
[TBL] [Abstract][Full Text] [Related]
14. Pemetrexed-induced cellulitis: a rare toxicity in non-small cell lung cancer treatment.
Katsenos S; Psara A; Panagou C
J Oncol Pharm Pract; 2013 Mar; 19(1):93-4. PubMed ID: 22357637
[TBL] [Abstract][Full Text] [Related]
15. Kidney tubular toxicity of maintenance pemetrexed therapy.
Glezerman IG; Pietanza MC; Miller V; Seshan SV
Am J Kidney Dis; 2011 Nov; 58(5):817-20. PubMed ID: 21849225
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of pemetrexed and cisplatin with concurrent high-dose thoracic radiation after induction chemotherapy in patients with unresectable locally advanced non-small cell lung cancer.
Mornex F; Peignaux K; Germain T; Wautot V; Chouaki N; Bourayou N; Tourani JM
Lung Cancer; 2013 Apr; 80(1):68-74. PubMed ID: 23332163
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of pemetrexed in patients pretreated with an anthracycline, a taxane, and capecitabine for advanced breast cancer.
O'Shaughnessy JA; Clark RS; Blum JL; Mennel RG; Snyder D; Ye Z; Liepa AM; Melemed AS; Yardley DA
Clin Breast Cancer; 2005 Jun; 6(2):143-9. PubMed ID: 16001992
[TBL] [Abstract][Full Text] [Related]
18. Phase I and pharmacokinetic study of pemetrexed plus cisplatin in chemonaive patients with locally advanced or metastatic malignant pleural mesothelioma or non-small cell lung cancer.
Dickgreber NJ; Fink TH; Latz JE; Hossain AM; Musib LC; Thomas M
Clin Cancer Res; 2009 Jan; 15(1):382-9. PubMed ID: 19118069
[TBL] [Abstract][Full Text] [Related]
19. PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.
Paz-Ares LG; de Marinis F; Dediu M; Thomas M; Pujol JL; Bidoli P; Molinier O; Sahoo TP; Laack E; Reck M; Corral J; Melemed S; John W; Chouaki N; Zimmermann AH; Visseren-Grul C; Gridelli C
J Clin Oncol; 2013 Aug; 31(23):2895-902. PubMed ID: 23835707
[TBL] [Abstract][Full Text] [Related]
20. Pemetrexed in first-line treatment of non-small cell lung cancer.
Esteban E; Casillas M; Cassinello A
Cancer Treat Rev; 2009 Jun; 35(4):364-73. PubMed ID: 19269106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
